Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Characteristics of patients on hemodialysis or peritoneal dialysisHD (n = 69)PD (n = 86)P ValueAge (years)52.1 ± 13.354.2 ± 11.70.306Dialysis vintage (months)38.0 (12.0,75.0)26.0 (12.8,58.0)0.084Male (n, %)47 (68.1)39 (45.4)0.006*DM (n, %)17 (24.6)36 (41.9)0.028*Primary causes of ESRD [n (%)] CGN38 (55.1)40 (46.5)0.289 DN14 (20.3)22 (25.6)0.438 CTIN6 (8.7)8 (9.3)0.896 HN4 (5.8)12 (14.0)0.107 Others7 (10.1)4 (4.6)0.294CVD in history, n (%)19 (27.5)21 (24.4)0.621BMI (Kg/m2)22.64 ± 3.6523.06 ± 3.600.476Time-averaged test value Hb (g/L)114.5 (111.0,116.4)115.6 (110.9117.3)0.345 Alb (g/L)40.1 ± 2.338.3 ± 2.9< 0.001* cCa (mmol/L)2.31 ± 0.342.38 ± 0.110.114 P (mmol/L)1.66 ± 0.371.56 ± 0.620.335 iPTH (pg/ml)170.6 (81.8363.2)187.9 (107.8340.8)0.615 Scr (umol/L)1043 ± 227960 ± 2730.078 CRP (mg/L)3.16 (1.53, 6.33)2.44 (1.54, 4.53)0.669 LDL-C (mmol/L)2.13 ± 0.582.97 ± 0.74< 0.001* HDL-C (mmol/L)0.92 (0.85, 1.09)1.06 (0.93, 1.28)0.006* T-Cho (mmol/L)4.24 ± 0.815.17 ± 0.96< 0.001* CRP (mg/L)3.16 (1.53, 6.33)2.44 (1.54, 4.53)0.669Medication use Calcium-based P bindera (n, %)56 (100.0)56 (88.9)0.029* Non-calcium-based P binderb (n, %)3 (5.3)12 (19.1)0.023* Cinacalcet (n, %)2 (3.5)1 (1.6)0.918 Vitamin D analogue (n, %)29 (50.9)15 (23.8)0.002* Baseline CAC Score97 (1744)95 (0, 324)0.361*P < 0.05 Notes: CGN: chronic glomerulonephritis; DN: diabetic nephropathy; CTIN: chronic tubulointerstitial nephropathy; HN: hypertensive nephropathy; BMI: body mass index; Hb: hemoglobin; Alb: albumin; cCa: corrected calcium; P: phosphate; iPTH: Intact Parathyroid Hormone; ALP: alkaline phosphatase; CO2CP: carbon dioxide combining power; Scr: serum creatinine; UA: uric acid; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; T-Cho: total cholesterol; a, calcium carbonate; b, lanthanum carbonate or sevelamer

Source: Demographic data and clinical characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This was a prospective cohort study.

Source: Abstract.

In our study, there were several patients have no detectable CAC at baseline and still no CAC at the end of 2-year follow up, so ∆ CAC scores of these patients were 0.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The effects of dialysis modalities on the progression of coronary artery calcification in dialysis patients

Cohort study · BMC Nephrology · 2020

Original publication title

The effects of dialysis modalities on the progression of coronary artery calcification in dialysis patients

Qingyu Niu; Huiping Zhao; Li Zuo; Mei Wang; Liangying Gan

© The Author(s) 2020

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

There was no evidence that different dialysis modalities have different effect on CAC progression. Old age, DM and higher time-averaged P were associated with fast CAC progression.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Hemodialysis (HD) tend to have more hemodynamic changes than peritoneal dialysis (PD), which aggravates inflammation and oxidative stress. Whether HD and PD have different effects on the progression of vascular calcification? Therefore, we produced a study to explore the relationship of dialysis modalities and coronary artery calcification (CAC) progression.

Source: Background

Abstract: What methods does the paper describe?

This was a prospective cohort study. CT scans were performed at enrollment and 2 years later for each patient. Demographic and clinical data were collected. Tobit regression was used to compare delta CAC score between HD and PD patients.

Source: Methods

Abstract: Results

(1) 155 patients were enrolled, including 69 HD and 86 PD patients. (2) The baseline CAC scores were 97 (1, 744) in HD and 95 (0, 324) in PD; the follow-up CAC scores were 343 (6, 1379) in HD and 293 (18, 997) in PD. There were no significant differences in baseline, follow-up and delta CAC scores between 2 groups (P > 0.05). (3) In Tobit regression, after adjusted for variables, there was no significant difference of CAC progression in HD and PD groups (P > 0.05). (4) Logistic regression showed that older age, diabetes and higher time-averaged serum phosphate (P) were associated with faster progression of CAC (P < 0.05), but there was no evidence that HD was associated with faster CAC progression compared with PD (P = 0.879).

Source: Results

Abstract: Conclusions

There was no evidence that different dialysis modalities have different effect on CAC progression. Old age, DM and higher time-averaged P were associated with fast CAC progression.

Source: Conclusions
Authors’ abstract

Background

Hemodialysis (HD) tend to have more hemodynamic changes than peritoneal dialysis (PD), which aggravates inflammation and oxidative stress. Whether HD and PD have different effects on the progression of vascular calcification? Therefore, we produced a study to explore the relationship of dialysis modalities and coronary artery calcification (CAC) progression.

Methods

This was a prospective cohort study. CT scans were performed at enrollment and 2 years later for each patient. Demographic and clinical data were collected. Tobit regression was used to compare delta CAC score between HD and PD patients.

Results

(1) 155 patients were enrolled, including 69 HD and 86 PD patients. (2) The baseline CAC scores were 97 (1, 744) in HD and 95 (0, 324) in PD; the follow-up CAC scores were 343 (6, 1379) in HD and 293 (18, 997) in PD. There were no significant differences in baseline, follow-up and delta CAC scores between 2 groups (P > 0.05). (3) In Tobit regression, after adjusted for variables, there was no significant difference of CAC progression in HD and PD groups (P > 0.05). (4) Logistic regression showed that older age, diabetes and higher time-averaged serum phosphate (P) were associated with faster progression of CAC (P < 0.05), but there was no evidence that HD was associated with faster CAC progression compared with PD (P = 0.879).

Conclusions

There was no evidence that different dialysis modalities have different effect on CAC progression. Old age, DM and higher time-averaged P were associated with fast CAC progression.

Publication and source details

Original title: The effects of dialysis modalities on the progression of coronary artery calcification in dialysis patients

Qingyu Niu; Huiping Zhao; Li Zuo; Mei Wang; Liangying Gan

BMC Nephrology · 2020

© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Capital Clinical Characteristics Application ProgramNo Z131107002213122Peking University Health Science Center Outstanding Doctoral Student Innovation FundNone

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T16:18:41.942199+00:00

DOI: 10.1186/s12882-020-01963-x · PMC7382852